Corinne Epperly
Directeur/Membre du Conseil chez IN8BIO, INC.
Fortune : 69 344 $ au 30/06/2024
Profil
Corinne D.
Epperly is an Independent Director at IN8bio, Inc. She previously served as an Independent Director at AVEO Pharmaceuticals, Inc. from 2021 to 2023.
Corinne also worked as a Research Analyst at Goldman Sachs International in 2010.
In addition, she held the position of Chief Operating Officer at Vascular Biogenics Ltd.
from 2017 to 2018 and Senior Vice President-Strategy & Operations at Iovance Biotherapeutics, Inc. from 2019 to 2020.
Corinne's most recent former position was as Chief Operating Officer at Cargo Therapeutics, Inc. from 2021 to 2023.
She holds graduate and doctorate degrees from The University of North Carolina at Charlotte.
Dr. Epperly's current job is as an Independent Director at IN8bio, Inc.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IN8BIO, INC.
0,19% | 12/06/2024 | 81 967 ( 0,19% ) | 69 344 $ | 30/06/2024 |
Postes actifs de Corinne Epperly
| Sociétés | Poste | Début |
|---|---|---|
| IN8BIO, INC. | Directeur/Membre du Conseil | 07/12/2023 |
Anciens postes connus de Corinne Epperly
| Sociétés | Poste | Fin |
|---|---|---|
| CARGO THERAPEUTICS, INC. | Directeur des opérations | 01/12/2023 |
| AVEO PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 19/01/2023 |
| IOVANCE BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2020 |
| NOTABLE LABS, LTD. | Directeur des opérations | 01/01/2018 |
Goldman Sachs International
 Goldman Sachs International Investment Banks/BrokersFinance Goldman Sachs International (GSI) is the Great Britain-based, wholly-owned brokerage subsidiary of Goldman Sachs Group UK Ltd., ultimately held by The Goldman Sachs Group, Inc. (NYSE: GS) in the US. The firm was founded in 1988 and formerly known as Trushelfco Ltd. Headquartered in London, GSI provides prime brokerage, securities lending, futures services and financing services for a range of clients such as corporations, financial institutions, governments and high-net worth individuals. | Analyst-Equity | 01/10/2010 |
Formation de Corinne Epperly
| The University of North Carolina at Charlotte | Doctorate Degree |
| University of Virginia | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
| CARGO THERAPEUTICS, INC. | Health Technology |
| IN8BIO, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
Vascular Biogenics Ltd.
 Vascular Biogenics Ltd. BiotechnologyHealth Technology Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel. | Health Technology |
Goldman Sachs International
Goldman Sachs International Investment Banks/BrokersFinance Goldman Sachs International (GSI) is the Great Britain-based, wholly-owned brokerage subsidiary of Goldman Sachs Group UK Ltd., ultimately held by The Goldman Sachs Group, Inc. (NYSE: GS) in the US. The firm was founded in 1988 and formerly known as Trushelfco Ltd. Headquartered in London, GSI provides prime brokerage, securities lending, futures services and financing services for a range of clients such as corporations, financial institutions, governments and high-net worth individuals. | Finance |
